ClinicalTrials.gg
RecruitingNCT07493551Updated Mar 25, 2026

A Bioequivalence Study of PP3M in Patients With Schizophrenia

An interventional study of Paliperidone Palmitate Injection (3M) in Schizophrenia, sponsored by CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-03-25.

Sponsored by CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. (part of CSPC Pharmaceutical Group Limited) · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 4 months after the study started (first participant enrolled Oct 2024, registered Mar 2026).
  • Started Oct 2024; still recruiting 2 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
260
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 115 studies testing paliperidone in Schizophrenia — 6 open to participants now, 6 under way, none of them phase 3. paliperidone · Schizophrenia.

Planned enrollment
42nd of 115
260 · median 178
Started
2024
the only one that year
No phase
4 of 115
1 open now
Registered
114th of 115
by date
Lead sponsor
2 of 115
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

Among the 115 studies testing paliperidone in Schizophrenia, this one is the 42nd largest by planned enrollment, is the only one that started in 2024, is one of 4 with no phase, and was the 114th registered.

Schizophrenia

3,574 studies on the registry are indexed under Schizophrenia; 496 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

6 of the 115 studies testing paliperidone in Schizophrenia are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

About paliperidone

paliperidone: first FDA approval 2006 (INVEGA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 334 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 259 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 115 studies testing paliperidone in Schizophrenia, or all of them as a file.
02

Study summary

To evaluate the bioequivalence of the test formulation paliperidone palmitate injection (3M) produced by CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. and the reference formulation paliperidone palmitate injection (3M) (brand name: Invega Trinza) by Janssen Pharmaceutica N.V. under multiple-dose administration.

Read the detailed description

A randomized, open-label, multi-center, two-drug, multiple-dose, parallel-design study was conducted among patients with schizophrenia in China to evaluate the bioequivalence of the test formulation paliperidone palmitate (3M) produced by CSPC zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. and the reference formulation paliperidone palmitate injection (3M) (trade name: Santodar) of Janssen Pharmaceutica N.V.

03

Conditions studied

  • Schizophrenia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 to 65 years old (including 18 and 65 years old).
  • Patients diagnosed with schizophrenia (by ICD-10 criteria) before screening.
  • Weight: male patients with weight ≥50.0 kg, female patients with weight ≥45.0 kg, with the of 19.0\~35.0 kg/m\^2 (including 19.0 and 35.0).
  • Positive and Negative Syndrome Scale (PANSS) total score lower than 70 at screening and baseline.
  • Clinical Global Impression-Severity (CGI-S) lower than 4 at screening and baseline.
  • Patients and their guardians voluntarily sign the ICF and are able to comply with the requirements of the study.

Exclusion criteria

Exclusion Criteria:

  • Be allergic, or have a clear history of allergies to trial drugs and components.
  • Patients with cardiovascular, liver, kidney, gastrointestinal, psychiatric, or neurological diseases that may affect participation in the trial, as determined by the investigator.
  • History of tardive dyskinesia.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
260 participants (estimated)

Study arms

  • Active comparator
    Test product

    Paliperidone Palmitate Injection (3M), 1.75 mL: 350 mg

    Drug: Paliperidone Palmitate Injection (3M)

  • Active comparator
    Reference product

    Invega Trinza, 1.75 mL: 350 mg

    Drug: Paliperidone Palmitate Injection (3M)

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax,ss,

    Maximum plasma concentration at steady state

    Time frame: Up to Day456

  2. AUCτ,ss

    Area under the plasma concentration-time curve over a dosing interval at steady state

    Time frame: Up to Day456

Secondary outcomes

  1. Title:Incidence and severity of adverse events (AEs)

    The frequency and degree of harmfulness of adverse events

    Time frame: Up to Day456

07

Study locations

1 of 1 sites recruiting
  • Beijing Anding Hospital Capital Medical University
    Beijing, Beijing Municipality 100120, China
    Recruiting
    • Gang Wang, M.D. · Contactadyyjg@163.com · 010-58303236
    • Gang Wang, M.D. · Principal investigator
    • Anning Li, M.D. · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Dec 2026, 26 months after the start.

Of 775 interventional studies with no phase under Schizophrenia, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 56. This study's planned 26 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2026
First posted
Mar 25, 2026
StartActual
Oct 9, 2024
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Mar 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07493551
Responsible party
Sponsor
First posted
Mar 25, 2026
Start date
Oct 9, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Mar 25, 2026

Study contacts

Clinical Trials Information Group officer
Contact
ctr-contact@cspc.cn
86-0311-69085587
Gang Wang, M.D.
principal investigator · Beijing Anding Hospital Capital Medical University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Paliperidone

Start the discussion